منابع مشابه
Bregging rights in ITP.
Just as we all have had our fill of the many articles on the T regulatory cell (Treg) abnormalities in immune thrombocytopenia (ITP), in this issue of Blood Li et al have identified a new regulatory player; the B regulatory cell (Breg).1 They find that Bregs have similar properties to Tregs in ITP; they are deficient in active disease and therapy that raises platelet counts also rescues the und...
متن کاملFcRn: an IgG Receptor on Phagocytes with a Novel Role in Phagocytosis Running title: Phagocyte FcRn
FcRn: an IgG Receptor on Phagocytes with a Novel Role in Phagocytosis Running title: Phagocyte FcRn Gestur Vidarsson, Annette M. Stemerding, Nigel M. Stapleton, Suzanne E. Spliethoff, Hans Janssen, Frank E.M. Rebers, Masja de Haas, and Jan G.J. van de Winkel 1) Immunotherapy Laboratory, Department of Immunology, University Medical Center Utrecht, The Netherlands, 2) Laboratory of Vaccine Resear...
متن کاملITP in the 21st century.
Immune (or idiopathic) thrombocytopenic purpura (ITP) is commonly encountered by the practicing hematologist. Clinical management decisions have traditionally been guided by individual training and past experience. Input from the literature has been more from observational reports of case series than from scientific results of hypothesis-driven research. Practice guidelines and several surveys ...
متن کاملThe Role of FcRn in Antigen Presentation
Immunoglobulins are unique molecules capable of simultaneously recognizing a diverse array of antigens and themselves being recognized by a broad array of receptors. The abundance specifically of the IgG subclass and the variety of signaling receptors to which it binds render this an important immunomodulatory molecule. In addition to the classical Fcγ receptors that bind IgG at the cell surfac...
متن کاملLenalidomide-Associated ITP
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a ca...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Blood
سال: 2021
ISSN: 2521-361X
DOI: 10.21037/aob-20-55